SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases

Zawawi, 2021, Profile of circulatory cytokines and chemokines in human coronaviruses: a systematic review and meta-analysis, Front. Immunol., 12, 666223, 10.3389/fimmu.2021.666223 Petrosillo, 2020, COVID-19, SARS and MERS: are they closely related?, Clin. Microbiol. Infect., 26, 729, 10.1016/j.cmi.2020.03.026 Liu, 2020, Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV, J. Med. Virol., 92, 491, 10.1002/jmv.25709 Abdelrahman, 2020, Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza A respiratory viruses, Front. Immunol., 11, 552909, 10.3389/fimmu.2020.552909 Sariol, 2020, Lessons for COVID-19 immunity from other coronavirus infections, Immunity, 53, 248, 10.1016/j.immuni.2020.07.005 de Wit, 2016, SARS and MERS: recent insights into emerging coronaviruses, Nat. Rev. Microbiol., 14, 523, 10.1038/nrmicro.2016.81 Yuan, 2017, Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains, Nat. Commun., 8, 15092, 10.1038/ncomms15092 Harmer, 2002, Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme, FEBS Lett., 532, 107, 10.1016/S0014-5793(02)03640-2 Ziegler, 2020, SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues, Cell, 181, 1016, 10.1016/j.cell.2020.04.035 Hamming, 2004, Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis, J. Pathol., 203, 631, 10.1002/path.1570 Lamers, 2020, SARS-CoV-2 productively infects human gut enterocytes, Science, 369, 50, 10.1126/science.abc1669 Sawalha, 2020, Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients, Clin. Immunol. Orlando Fla, 215, 108410, 10.1016/j.clim.2020.108410 Bost, 2022, Long non-coding RNA Xist contribution in systemic lupus erythematosus and rheumatoid arthritis, Clin. Immunol. Orlando Fla, 236, 108937, 10.1016/j.clim.2022.108937 Tang, 2021, Decreased serum ACE2 levels in patients with connective tissue diseases, Rheumatol. Oxf. Engl., 60, 4401, 10.1093/rheumatology/keaa898 Fagyas, 2022, Circulating ACE2 activity predicts mortality and disease severity in hospitalized COVID-19 patients, Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis., 115, 8 Takahashi, 2010, Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases, Arthritis Res. Ther., 12, R85, 10.1186/ar3012 Keewan, 2021, Anti-TNF-α agents modulate SARS-CoV-2 receptors and increase the risk of infection through notch-1 signaling, Front. Immunol., 12, 641295, 10.3389/fimmu.2021.641295 Zhang, 2020, Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19, Int. Immunopharm., 86, 106749, 10.1016/j.intimp.2020.106749 Sun, 2020, The kinetics of viral load and antibodies to SARS-CoV-2, Clin. Microbiol. Infect., 26, 1690.e1, 10.1016/j.cmi.2020.08.043 Néant, 2021, Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort, Proc. Natl. Acad. Sci. U. S. A., 118, 10.1073/pnas.2017962118 Li, 2021, Persistent SARS-CoV-2-positive over 4 months in a COVID-19 patient with CHB, Open Med., 16, 749, 10.1515/med-2021-0283 Agarwal, 2020, Long-term SARS-CoV-2 RNA shedding and its temporal association to IgG seropositivity, Cell Death Dis., 6, 138, 10.1038/s41420-020-00375-y Chen, 2020, The presence of SARS‐CoV‐2 RNA in the feces of COVID‐19 patients, J. Med. Virol., 92, 833, 10.1002/jmv.25825 Yang, 2020, A convalescent of COVID-19 with RT-PCR test continues positive in stool, Clin. Lab., 66, 10.7754/Clin.Lab.2020.200623 Rizzo, 2021, SARS-CoV-2 nucleocapsid protein and ultrastructural modifications in small bowel of a 4-week-negative COVID-19 patient, Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis., 27, 936 Neurath, 2021, Gut as viral reservoir: lessons from gut viromes, HIV and COVID-19, Gut, 70, 1605, 10.1136/gutjnl-2021-324622 Proal, 2021, Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms, Front. Microbiol., 12, 698169, 10.3389/fmicb.2021.698169 Birra, 2020, Covid 19: a clue from innate immunity, Immunol. Res., 68, 161, 10.1007/s12026-020-09137-5 Totura, 2015, Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection, mBio, 6, 10.1128/mBio.00638-15 Sariol, 2020, Lessons for COVID-19 immunity from other coronavirus infections, Immunity, 53, 248, 10.1016/j.immuni.2020.07.005 Manik, 2021, Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19, J. Med. Virol. Han, 2021, SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways, J. Med. Virol., 93, 5376, 10.1002/jmv.27050 Bastard, 2020, Autoantibodies against type I IFNs in patients with life-threatening COVID-19, Science, 370, 10.1126/science.abd4585 Zhang, 2020, Inborn errors of type I IFN immunity in patients with life-threatening COVID-19, Science, 370, eabd4570, 10.1126/science.abd4570 Arleevskaya, 2020, Toll-like receptors, infections, and rheumatoid arthritis, Clin. Rev. Allergy Immunol., 58, 172, 10.1007/s12016-019-08742-z Gupta, 2020, Association between anti-interferon-alpha autoantibodies and COVID-19 in systemic lupus erythematosus, MedRxiv Prepr. Serv. Health Sci. Bettacchioli, 2021, An elevated polyclonal free light chain level reflects a strong interferon signature in patients with systemic autoimmune diseases, J. Transl. Autoimmun., 4, 100090, 10.1016/j.jtauto.2021.100090 Barturen, 2021, Integrative analysis reveals a molecular stratification of systemic autoimmune diseases, Arthritis Rheumatol, 73, 1073, 10.1002/art.41610 Simon, 2021, A proinflammatory cytokine network profile in Th1/type 1 effector B cells delineates a common group of patients in four systemic autoimmune diseases, Arthritis Rheumatol., 73, 1550, 10.1002/art.41697 Morimoto, 2011, Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus, Arthritis Rheum., 63, 2407, 10.1002/art.30399 Gupta, 2016, Distinct functions of autoantibodies against interferon in systemic lupus erythematosus: a comprehensive analysis of anticytokine autoantibodies in common rheumatic diseases, Arthritis Rheumatol. Hoboken NJ, 68, 1677, 10.1002/art.39607 Gallucci, 2021, Abnormalities of the type I interferon signaling pathway in lupus autoimmunity, Cytokine, 146, 155633, 10.1016/j.cyto.2021.155633 Chaichian, 2019, A promising approach to targeting type 1 IFN in systemic lupus erythematosus, J. Clin. Invest., 129, 958, 10.1172/JCI127101 Morand, 2020, Trial of anifrolumab in active systemic lupus erythematosus, N. Engl. J. Med., 382, 211, 10.1056/NEJMoa1912196 Cenac, 2022, Hydroxychloroquine inhibits proteolytic processing of endogenous TLR7 protein in human primary plasmacytoid dendritic cells, Eur. J. Immunol., 52, 54, 10.1002/eji.202149361 Wilkinson, 2020, The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis, Arthritis Res. Ther., 22, 102, 10.1186/s13075-020-02177-0 Koh, 2020, Biologics targeting type I interferons in SLE: a meta-analysis and systematic review of randomised controlled trials, Lupus, 29, 1845, 10.1177/0961203320959702 Wang, 2020, Excessive neutrophils and neutrophil extracellular traps in COVID-19, Front. Immunol., 11, 2063, 10.3389/fimmu.2020.02063 Wang, 2020, Definition and risks of cytokine release syndrome in 11 critically ill COVID-19 patients with pneumonia: analysis of disease characteristics, J. Infect. Dis., 222, 1444, 10.1093/infdis/jiaa387 Xiang, 2021, SARS-CoV-2 induces lymphocytopenia by promoting inflammation and decimates secondary lymphoid organs, Front. Immunol., 12, 661052, 10.3389/fimmu.2021.661052 Luporini, 2021, IL-6 and IL-10 are associated with disease severity and higher comorbidity in adults with COVID-19, Cytokine, 143, 155507, 10.1016/j.cyto.2021.155507 Chen, 2020, Clinical and immunological features of severe and moderate coronavirus disease 2019, J. Clin. Invest., 130, 2620, 10.1172/JCI137244 Quirch, 2020, Hazards of the cytokine storm and cytokine-targeted therapy in patients with COVID-19: review, J. Med. Internet Res., 22, 10.2196/20193 Kong, 2022, The role of NLRP3 inflammasome in the pathogenesis of rheumatic disease, Autoimmunity, 55, 1, 10.1080/08916934.2021.1995860 Li, 2020, Role of the NLRP3 inflammasome in autoimmune diseases, Biomed. Pharmacother. Biomedecine Pharmacother., 130, 110542, 10.1016/j.biopha.2020.110542 Grimaudo, 2021, PNPLA3 and TLL-1 polymorphisms as potential predictors of disease severity in patients with COVID-19, Front. Cell Dev. Biol., 9, 627914, 10.3389/fcell.2021.627914 Hsueh, 2004, Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus, Clin. Microbiol. Infect., 10, 1062, 10.1111/j.1469-0691.2004.01009.x Oliveira-Silva, 2022, Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: real-world data from a large cohort of healthcare workers, Vaccine, 40, 650, 10.1016/j.vaccine.2021.12.014 Legros, 2021, A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity, Cell. Mol. Immunol., 18, 318, 10.1038/s41423-020-00588-2 Woodruff, 2020, Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19, Nat. Immunol., 21, 1506, 10.1038/s41590-020-00814-z Hoehn, 2021, Cutting edge: distinct B cell repertoires characterize patients with mild and severe COVID-19, J. Immunol. Baltim. Md 1950, 206, 2785 Kaneko, 2020 Martinez-Gamboa, 2006, Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy, Autoimmun. Rev., 5, 437, 10.1016/j.autrev.2006.02.004 Wang, 2020, The laboratory tests and host immunity of COVID-19 patients with different severity of illness, JCI Insight, 5, 10.1172/jci.insight.137799 Kong, 2020, Storm of soluble immune checkpoints associated with disease severity of COVID-19, Signal Transduct. Targeted Ther., 5, 192, 10.1038/s41392-020-00308-2 Zheng, 2020, Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients, Cell. Mol. Immunol., 17, 541, 10.1038/s41423-020-0401-3 Fan, 2009, Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection, Arch. Virol., 154, 1093, 10.1007/s00705-009-0409-6 Oh, 2011, Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope, J. Virol., 85, 10464, 10.1128/JVI.05039-11 Tang, 2011, Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study, J. Immunol., 186, 7264, 10.4049/jimmunol.0903490 Renaudineau, 2022, Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response, Clin. Immunol., 237, 10.1016/j.clim.2022.108979 Liu, 2017, T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV, Antivir. Res., 137, 82, 10.1016/j.antiviral.2016.11.006 Chen, 2010, Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4 + T cells are important in control of SARS-CoV infection, J. Virol., 84, 1289, 10.1128/JVI.01281-09 Zhao, 2010, T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice, J. Virol., 84, 9318, 10.1128/JVI.01049-10 Lingel, 2021, Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals, J. Autoimmun., 122, 102682, 10.1016/j.jaut.2021.102682 Dotan, 2021, The SARS-CoV-2 as an instrumental trigger of autoimmunity, Autoimmun. Rev., 20, 102792, 10.1016/j.autrev.2021.102792 Taha, 2021, Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review, RMD Open, 7, 10.1136/rmdopen-2021-001580 Borghi, 2020, Anti-Phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome, Front. Immunol., 11, 584241, 10.3389/fimmu.2020.584241 Arvieux, 2002, Distinguishing features of anti-beta 2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome, Thromb. Haemostasis, 87, 599, 10.1055/s-0037-1613055 Bettacchioli, 2019, News and meta-analysis regarding anti-Beta 2 glycoprotein I antibodies and their determination, Clin. Immunol. Orlando Fla, 205, 106, 10.1016/j.clim.2019.06.002 Lerma, 2020, Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19), J. Transl. Autoimmun., 3, 100073, 10.1016/j.jtauto.2020.100073 Gazzaruso, 2020, High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia, Clin. Rheumatol., 39, 2095, 10.1007/s10067-020-05180-7 Anaya, 2021, Latent rheumatic, thyroid and phospholipid autoimmunity in hospitalized patients with COVID-19, J. Transl. Autoimmun., 4, 100091, 10.1016/j.jtauto.2021.100091 Renaudineau, 2005, Rheumatoid factor on a daily basis, Autoimmunity, 38, 11, 10.1080/08916930400022574 Litwin, 2016, ANA testing in the presence of acute and chronic infections, J. Immunoassay Immunochem., 37, 439, 10.1080/15321819.2016.1174136 Bayry, 2005, Natural autoantibodies: immune homeostasis and therapeutic intervention, Expet Rev. Clin. Immunol., 1, 213, 10.1586/1744666X.1.2.213 Arleevskaya, 2016, How rheumatoid arthritis can result from provocation of the immune system by microorganisms and viruses, Front. Microbiol., 7, 1296, 10.3389/fmicb.2016.01296 Zulfiqar, 2020, Immune thrombocytopenic purpura in a patient with covid-19, N. Engl. J. Med., 382, e43, 10.1056/NEJMc2010472 Gracia-Ramos, 2021, Can the SARS-CoV-2 infection trigger systemic lupus erythematosus? A case-based review, Rheumatol. Int., 41, 799, 10.1007/s00296-021-04794-7 Baimukhamedov, 2021, Seropositive rheumatoid arthritis after vaccination against SARS-CoV-2 infection, Int. J. Rheum. Dis., 24, 1440, 10.1111/1756-185X.14220 Sharma, 2021, Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison, Nat. Rev. Rheumatol., 17, 731, 10.1038/s41584-021-00709-9 Kanduc, 2020, From anti-SARS-CoV-2 immune responses to COVID-19 via molecular mimicry, Antibodies Basel Switz, 9, E33, 10.3390/antib9030033 Damoiseaux, 2021, Autoantibodies and SARS-CoV2 infection: the spectrum from association to clinical implication: report of the 15th Dresden Symposium on Autoantibodies, Autoimmun. Rev., 21, 103012, 10.1016/j.autrev.2021.103012 Arisan, 2020, Putative roles for peptidylarginine deiminases in COVID-19, Int. J. Mol. Sci., 21, E4662, 10.3390/ijms21134662 Demoruelle, 2017, Anti-citrullinated protein antibodies are associated with neutrophil extracellular traps in the sputum in relatives of rheumatoid arthritis patients, Arthritis Rheumatol. Hoboken NJ, 69, 1165, 10.1002/art.40066 Zuo, 2020, Neutrophil extracellular traps in COVID-19, JCI Insight, 5, 138999 Cavalier, 2021, Circulating nucleosomes as potential markers to monitor COVID-19 disease progression, Front. Mol. Biosci., 8, 600881, 10.3389/fmolb.2021.600881 Perrot, 2021, First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection, Lanc. Rheumatol., 3, e6, 10.1016/S2665-9913(20)30396-9 Mageau, 2021, Survival after COVID-19-associated organ failure among inpatients with systemic lupus erythematosus in France: a nationwide study, Ann. Rheum. Dis., 10.1136/annrheumdis-2021-220010 Sakthiswary, 2021, COVID-19 in systemic lupus erythematosus: a pooled analysis and systematic review of case reports and series, Lupus, 30, 1946, 10.1177/09612033211045057 Holubar, 2020, Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak, Ann. Rheum. Dis. Zucchi, 2021, Impact of first wave of SARS-CoV-2 infection in patients with Systemic Lupus Erythematosus: weighting the risk of infection and flare, PLoS One, 16, 10.1371/journal.pone.0245274 Jung, 2021, Association between previous rheumatoid arthritis and COVID-19 and its severity: a nationwide cohort study in South Korea, BMJ Open, 11, 10.1136/bmjopen-2021-054753 Saadoun, 2021, SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study, Lanc. Rheumatol., 3, e481, 10.1016/S2665-9913(21)00112-0 Gianfrancesco, 2020, Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann. Rheum. Dis., 79, 859, 10.1136/annrheumdis-2020-217871 Akiyama, 2020, Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis, Ann. Rheum. Dis. Sparks, 2021, Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry, Ann. Rheum. Dis., 80, 1137, 10.1136/annrheumdis-2021-220418 Pileggi, 2021, Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil, Adv. Rheumatol. Lond. Engl., 61, 60, 10.1186/s42358-021-00217-0 Kalil, 2021, Baricitinib plus remdesivir for hospitalized adults with covid-19, N. Engl. J. Med., 384, 795, 10.1056/NEJMoa2031994 Joo, 2021, Influenza infection as a trigger for systemic lupus erythematosus flares resulting in hospitalization, Sci. Rep., 11, 4630, 10.1038/s41598-021-84153-5 Joo, 2021, Association of influenza infection with hospitalisation-related systemic lupus erythematosus flares: a time series analysis, Clin. Exp. Rheumatol., 39, 1056, 10.55563/clinexprheumatol/fmkp4b Lee, 2020, Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19, Sci. Immunol., 5, 10.1126/sciimmunol.abd1554 Blumentals, 2012, Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study, BMC Muscoskel. Disord., 13, 158, 10.1186/1471-2474-13-158 Larionova, 2019, In seroconverted rheumatoid arthritis patients a multi-reactive anti-herpes IgM profile is associated with disease activity, Clin. Immunol. Orlando Fla, 200, 19, 10.1016/j.clim.2019.01.004 Arleevskaya, 2017, Associations between viral infection history symptoms, granulocyte reactive oxygen species activity, and active rheumatoid arthritis disease in untreated women at onset: results from a longitudinal cohort study of tatarstan women, Front. Immunol., 8, 1725, 10.3389/fimmu.2017.01725 Arleevskaya, 2018, Prevalence and incidence of upper respiratory tract infection events are elevated prior to the development of rheumatoid arthritis in first-degree relatives, Front. Immunol., 9, 2771, 10.3389/fimmu.2018.02771 Smeele, 2021, Systemic lupus erythematosus and COVID-19 during pregnancy, Lupus, 30, 1188, 10.1177/09612033211002270 Izmirly, 2022, Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS-CoV-2 vaccination, Arthritis Rheumatol. Hoboken NJ, 74, 284, 10.1002/art.41937 Spinelli, 2022, Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine, Arthritis Res. Ther., 24, 21, 10.1186/s13075-021-02674-w Moody, 2021, Adaptive immunity and the risk of autoreactivity in COVID-19, Int. J. Mol. Sci., 22, 8965, 10.3390/ijms22168965 Chen, 2021, New-onset autoimmune phenomena post-COVID-19 vaccination, Immunology Crivelenti, 2021, Chronic arthritis related to SARS-CoV-2 infection in a pediatric patient: a case report, Braz. J. Infect. Dis., 25, 101585, 10.1016/j.bjid.2021.101585 Zamani, 2021, Systemic lupus erythematosus manifestation following COVID-19: a case report, J. Med. Case Rep., 15, 29, 10.1186/s13256-020-02582-8 Slimani, 2021, Systemic lupus erythematosus and varicella‐like rash following COVID‐19 in a previously healthy patient, J. Med. Virol., 93, 1184, 10.1002/jmv.26513 Mantovani Cardoso, 2020, Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology, Clin. Rheumatol., 39, 2811, 10.1007/s10067-020-05310-1 Tang, 2021, Autoimmune and rheumatic manifestations associated with COVID-19 in adults: an updated systematic review, Front. Immunol., 12, 645013, 10.3389/fimmu.2021.645013 Bonometti, 2020, The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection, Eur. Rev. Med. Pharmacol. Sci., 24, 9695 Alivernini, 2021, Comparative analysis of synovial inflammation after SARS-CoV-2 infection, Ann. Rheum. Dis., 80, 10.1136/annrheumdis-2020-218315 Talarico, 2020, Symmetric peripheral polyarthritis developed during SARS-CoV-2 infection, Lanc. Rheumatol., 2, e518, 10.1016/S2665-9913(20)30216-2 Derksen, 2021, Onset of rheumatoid arthritis after COVID-19: coincidence or connected?, Ann. Rheum. Dis., 80, 1096, 10.1136/annrheumdis-2021-219859 Joo, 2019, Respiratory viral infections and the risk of rheumatoid arthritis, Arthritis Res. Ther., 21, 199, 10.1186/s13075-019-1977-9 Nalbandian, 2021, Post-acute COVID-19 syndrome, Nat. Med., 27, 601, 10.1038/s41591-021-01283-z Kaul, 2016, Systemic lupus erythematosus, Nat. Rev. Dis. Prim., 2, 16039, 10.1038/nrdp.2016.39 Smolen, 2018, Rheumatoid arthritis, Nat. Rev. Dis. Prim., 4, 18001, 10.1038/nrdp.2018.1 Ng, 2021, Circulating markers of neutrophil extracellular traps are of prognostic value in patients with COVID-19, Arterioscler. Thromb. Vasc. Biol., 41, 988, 10.1161/ATVBAHA.120.315267 Elliott, 2021, PAD inhibitors as a potential treatment for SARS-CoV-2 immunothrombosis, Biomedicines, 9, 1867, 10.3390/biomedicines9121867 Su, 2022, Multiple early factors anticipate post-acute COVID-19 sequelae, Cell, 10.1016/j.cell.2022.01.014 Hiroki, 2021, Innate receptors expression by lung nociceptors: impact on COVID-19 and aging, Front. Immunol., 12, 785355, 10.3389/fimmu.2021.785355 Antonio, 2005, Radiographic-clinical correlation in severe acute respiratory syndrome: study of 1373 patients in Hong Kong, Radiology, 237, 1081, 10.1148/radiol.2373041919 Rainer, 2003, Evaluation of WHO criteria for identifying patients with severe acute respiratory syndrome out of hospital: prospective observational study, BMJ, 326, 1354, 10.1136/bmj.326.7403.1354 Eslambolchi, 2021, Coronavirus disease 2019 (COVID-19) in patients with systemic autoimmune diseases or vasculitis: radiologic presentation, J. Thromb. Thrombolysis, 51, 339, 10.1007/s11239-020-02289-z Shimoyama, 2022, Surgically treated reactive arthritis of the ankle after COVID-19 infection: a case report, J. Infect. Chemother. Off. J. Jpn. Soc. Chemother., 10.1016/j.jiac.2021.12.028 Kuschner, 2021, A case of SARS-CoV-2-associated arthritis with detection of viral RNA in synovial fluid, J. Am. Coll. Emerg. Physicians Open, 2 Zeidler, 2021, [Post-Corona-Virus-Disease-19 arthritis. Manifestation under the clinical picture of a reactive arthritis], Z. Rheumatol., 80, 555, 10.1007/s00393-021-01045-9 Arleevskaya, 2021, Causal risk and protective factors in rheumatoid arthritis: A genetic update, Transl. Autoimmun., 4